Molecular mechanism of the NKCC transporter
NKCC转运蛋白的分子机制
基本信息
- 批准号:9767115
- 负责人:
- 金额:$ 3.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2021-12-14
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesBasic ScienceBindingBinding SitesBiological AssayBody partBumetanideCell membraneChlorthalidoneCirrhosisClinicClinicalCoupledCouplingCryoelectron MicroscopyDataDehydrationDevelopmentDiseaseDiureticsDrug InteractionsDrug TargetingEdemaEnvironmentEventFamilyFamily memberFurosemideGoalsHeart failureHomeostasisHydrochlorothiazideHypertensionHypokalemiaIn VitroIndividualInterdisciplinary StudyIon TransportIonsKidneyKnowledgeLipid BilayersLipidsLiposomesMedicineMembrane ProteinsMentorsModificationMolecularMolecular ConformationMutagenesisNegative StainingNephrotic SyndromeParticle SizePatientsPharmaceutical PreparationsPharmacologic SubstancePhosphorylationPhysiologyPost-Translational Protein ProcessingPotassium ChloridePropertyProtein FamilyProteinsResearchResolutionRoleSLC12A3 geneSamplingSodiumSodium ChlorideSodium-Potassium-Chloride SymportersSpecificityStructural ProteinStructureSubstrate SpecificitySystemTechniquesThiazide Diureticsblood pressure regulationcomputer studiesdesigndrug developmentexperienceexperimental studyextracellularglycosylationgraduate studenthearing impairmentinhibitor/antagonistinsightmemberparticleprotein functionprotein structurereconstitutionside effectsolutestoichiometry
项目摘要
Abstract
The sodium-potassium-chloride-cotransporter (NKCC) family of transporters are critical to the reabsorption of
ions in the kidney and other parts of the body. As a member of the larger solute carrier 12 (SLC12A) family,
these transporters move sodium, potassium, and chloride across the cell membrane in order to maintain ionic
homeostasis and regulate blood pressure. As a result of their important roles in physiology, they are also
among the most widely targeted transporters in medicine. Drugs such as the loop diuretics and thiazide
diuretics have been in use for decades, and are fundamental medications to treating conditions such as
edema, cirrhosis, heart failure, and hypertension. Yet despite their widespread use, little is known about the
molecular mechanism by which they operate. This project will address that gap in knowledge, by studying the
NKCC group of transporters from a fundamental, basic science perspective. An in vitro functional assay will be
developed in order to study the transport mechanism of NKCC in a well-defined system. Key components
responsible for ion recognition and binding, as well as inhibitor binding sites will be determined using
mutagenesis coupled with functional assays. The above knowledge will be combined with structural
characterizations about NKCC to understand its function. As a whole, this study will reveal the fundamental
mechanisms about how NKCC transporters operate and how they are targeted. This information will lead to
better pharmaceuticals, with fewer side effects.
摘要
钠-钾-氯化物-协同转运蛋白(NKCC)家族转运蛋白对药物的重吸收至关重要。
肾脏和身体其他部位的离子。作为较大溶质载体12(SLC 12 A)家族的成员,
这些转运蛋白使钠、钾和氯穿过细胞膜,以维持离子
体内平衡和调节血压。由于它们在生理学中的重要作用,它们也
是医学上最广泛的靶向转运蛋白之一。袢利尿剂和噻嗪类药物
利尿剂已经使用了几十年,并且是治疗以下病症的基本药物,
水肿、肝硬化、心力衰竭和高血压。然而,尽管它们被广泛使用,但人们对它们知之甚少。
它们运作的分子机制。本项目将通过研究
NKCC运输集团从一个基本的,基础科学的角度。将进行体外功能测定,
为了研究NKCC在一个定义明确的系统中的传输机制而开发的。关键部件
负责离子识别和结合以及抑制剂结合位点将使用
诱变结合功能测定。上述知识将结合结构
对NKCC的描述,以了解其功能。作为一个整体,这项研究将揭示基本的
关于NKCC运输者如何运作以及他们如何成为目标的机制。这些信息将导致
更好的药物,副作用更少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Chew其他文献
Thomas Chew的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Chew', 18)}}的其他基金
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 3.85万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 3.85万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 3.85万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 3.85万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 3.85万 - 项目类别:














{{item.name}}会员




